reports
Novonesis and Novo Nordisk will explore new solutions to improve metab...
Novonesis and Novo Nordisk will explore new solutions to improve metabolic health Novonesis and Novo Nordisk join forces in a new research collaboration to explore solutions that seek to preserve and optimize metabolic health and well-being for people. COPENHAGEN, Denmark – September 8, 2025. Novonesis and Novo Nordisk has entered a research partnership to explore the role of the gut microbiome in the maintenance of metabolic health. The gut microbiome is the collection of microorganisms, such as bacteria, fungi, and viruses, that naturally live in the human gut. The science...
Vestas Wind Systems AS: 1 director
A director at Vestas Wind Systems AS maiden bought 6,000 shares at 124.180DKK and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Jan Erik Gjerland
- Simon Brun
Novonesis delivered 9% organic sales growth in H1 and full-year outloo...
Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8% COPENHAGEN, Denmark – August 21, 2025. Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%. Ester Baiget, President & CEO: “I’m very pleased with 9% organic sales growth in the first half of the year. Demand for our biosolutions is strong, and consequently, we are lifting the lower end of our full-year guidance to 6-8% organic sales growth. Our profitability also remains solid, despite strong headwinds from currencies. With a strong foundation in place, ...
Interim report H1 2025
Interim report H1 2025 9% organic sales growth in H1 and FY outlook range narrowed to 6-8% Ester Baiget, President & CEO: “I’m very pleased with 9% organic sales growth in the first half of the year. Demand for our biosolutions is strong, and consequently, we are lifting the lower end of our full-year guidance to 6-8% organic sales growth. Our profitability also remains solid, despite strong headwinds from currencies. With a robust foundation in place, we are well positioned to accelerate into our next strategy period until 2030, where we will continue to significantly invest in what mak...
2030 financial targets announced: Organic sales growth acceleration, m...
2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement COPENHAGEN, Denmark - August 20, 2025. Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re-investments to secure long-term growth. By 2030, the company expects to deliver an organic sales CAGR of 6-9%, an adjusted EBITDA margin of ~39% and an adjusted ROIC excl. goodwill of ~16%. Novonesis is well positioned to continue to drive strong performance in biosolutions. The...
2030 financial targets announced: Organic sales growth acceleration, m...
2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re-investments to secure long-term growth. By 2030, the company expects to deliver an organic sales CAGR of 6-9%, an adjusted EBITDA margin of ~39% and an adjusted ROIC excl. goodwill of ~16%. Novonesis is well positioned to continue to drive strong performance in biosolutions. The company is present across multiple end...
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Jan Erik Gjerland
- Simon Brun
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Jan Erik Gjerland
- Simon Brun
- ABGSC Media Research
- Derek Laliberté
- ABGSC Media Research
- Derek Laliberté
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Jan Erik Gjerland
- Simon Brun
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Jan Erik Gjerland
- Simon Brun
- ABGSC Media Research
- Derek Laliberté
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.